Sharekhan

Windlas Biotech Ltd

Fri 22/05/2026,15:57:59 | NSE : WINDLAS

₹ 789.957.60 (0.97%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 784.10

Previous Close

₹ 782.35

Volume

200469

Mkt Cap ( Rs. Cr)

₹1657.97

High

₹ 796.90

Low

₹ 752.00

52 Week High

₹ 1097.90

52 Week Low

₹ 697.40

Book Value Per Share

₹ 261.59

Dividend Yield

0.00

Face Value

₹ 5.00

What’s Your Call?

Collective community sentiment on Windlas Biotech Ltd

Your Vote -

Buy

21.74%

Hold

56.52%

Sell

21.74%

21.74%

46 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

789.95

227

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

227

Option Chain

Analyzes market sentiment, predicts Windlas Biotech Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    22 May 2026, 4:37PM Windlas Biotech Limited has informed the Exchange about Link of Recording
  • Windlas Biotech - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2

    22 May 2026, 4:34PM Audio recording of Investors/ Analyst conference call on the audited consolidated and standalone financial results of the Company for the quarter and
  • Windlas Biotech - Updates

    21 May 2026, 6:44PM Windlas Biotech Limited has informed the Exchange regarding Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requi
  • Windlas Biotech - Intimation Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements), Regulat

    21 May 2026, 6:39PM Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 regarding grant of Stock Options
  • Windlas Biotech - Press Release

    21 May 2026, 5:34PM Windlas Biotech Limited has informed the Exchange regarding a press release dated May 21, 2026, titled "" Windlas Biotech Limited Reports its Q4 and F
  • Windlas Biotech - Investor Presentation

    21 May 2026, 5:22PM Windlas Biotech Limited has informed the Exchange about Investor Presentation
  • Windlas Biotech - Outcome of Board Meeting

    21 May 2026, 5:06PM Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026, and recommendation of dividend
  • Windlas Biotech - Disclosure under SEBI Takeover Regulations

    21 May 2026, 10:54AM Manoj Kumar Windlass has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substant
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    21 May 2026, 5:38PM 'Windlas Biotech Limited Reports its Q4 and FY26 Financial Results'
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Investor Presentation

    21 May 2026, 5:26PM Investor Presentation - Q4 & FY26
  • Windlas Biotech Q4 net profit down 1.66% at Rs 16.02 cr

    21 May 2026, 5:00PM The company reported standalone net profit of Rs 16.02 crore for the quarter ended March 31, 2026 as compared to Rs 16.29 crore in the same period las
  • Windlas Biotech - Approval Of Audited Consolidated And Standalone Financial Results For The Year Ended March 31, 2026 Along W

    21 May 2026, 4:53PM Approval of audited consolidated and standalone financial results for the year ended March 31, 2026 along with recommendation of final dividend
  • Windlas Biotech - Board Meeting Outcome for Outcome Of The Board Meeting

    21 May 2026, 4:34PM Approval of audited consolidated and standalone financial results and recommendation of dividend
  • Windlas Biotech - General Updates

    18 May 2026, 10:48PM Windlas Biotech Limited has informed the Exchange about Update regarding Labour Protest in Dehradun
  • Windlas Biotech - Update Regarding Labour Protest In Dehradun\r\n

    18 May 2026, 10:44PM Update regarding Labour Protest in Dehradun
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    18 May 2026, 6:55PM Schedule of Conference Call to discuss financial performance for quarter and financial year ended March 31, 2026
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    18 May 2026, 6:49PM Windlas Biotech Limited has informed the Exchange about Schedule of meet
  • Windlas Biotech - Closure of Buy Back

    18 May 2026, 6:16PM Windlas Biotech Limited has informed the Exchange regarding Closure of Buy Back with effect from May 16, 2026
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Closure of Buy Back

    18 May 2026, 5:56PM Completion of Extinguishment of 4,70,000 fully paid-up equity shares of face value of INR 5 each pursuant to buyback of Windlas Biotech Limited (the '
  • Windlas Biotech - Submission Of Post Buyback Public Announcement

    16 May 2026, 12:40PM Post Buyback Public Advertisement pursuant to and in compliance with Buyback Regulations. The Post Buyback Public Advertisement dated May 15, 2026 has
  • Windlas Biotech - Copy of Newspaper Publication

    16 May 2026, 12:34PM Windlas Biotech Limited has informed the Exchange about Copy of Newspaper Publication for Post Buyback Public Announcement
  • Windlas Biotech - Board Meeting Intimation for Notice Of The Board Meeting Scheduled To Be Held On Thursday, May 21, 2026

    15 May 2026, 2:13PM Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and
  • Windlas Biotech - Outcome of Board Meeting

    5 May 2026, 6:15PM Windlas Biotech Limited has informed the Exchange regarding Outcome of Board Meeting held on May 05, 2026.
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Change in Directorate

    5 May 2026, 6:10PM Appointment of Dr. Tarashree Singhal as Independent Woman Director and cessation of directorship of Mr. Srinivasan Venkataraman.
  • Windlas Biotech - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

    30 Apr 2026, 1:06PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td
  • Windlas Biotech - Copy of Newspaper Publication

    29 Apr 2026, 12:57PM Windlas Biotech Limited has informed the Exchange about Copy of Newspaper Publication
  • Windlas Biotech - Buyback

    27 Apr 2026, 6:39PM Windlas Biotech Limited has informed the Exchange about submission of Letter of Offer for Buyback
  • Windlas Biotech - Submission Of Letter Of Offer

    27 Apr 2026, 6:34PM Buyback of 4,70,000 (Four Lakh Seventy Thousand) fully paid-up Equity Shares of the face value of INR 5 each ('Equity Shares') of Windlas Biotech Limi
  • Windlas Biotech - Copy of Newspaper Publication

    20 Apr 2026, 3:50PM Windlas Biotech Limited has informed the Exchange about Copy of Newspaper Publication on submission of copy of Public Announcement pertaining to the B
  • Windlas Biotech - Record Date

    17 Apr 2026, 2:32PM Windlas Biotech Limited has informed the Exchange that Record date for the purpose of BB is 24-Apr-2026.
  • Windlas Biotech - Record Date

    17 Apr 2026, 2:26PM Regulation 30 and Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SE
  • Windlas Biotech - Outcome of Board Meeting

    17 Apr 2026, 2:10PM Windlas Biotech Limited has informed the Exchange regarding Outcome of Board Meeting held on April 17, 2026.
  • Windlas Biotech - Board Meeting Outcome for Regulation 30 And Regulation 42 Of The Securities And Exchange Board Of India (Li

    17 Apr 2026, 2:03PM Regulation 30 and Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SE
  • Windlas Biotech has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026

    15 Apr 2026, 6:00PM As of March 2026, 61.90% is owned by Indian Promoters and 38.10% by Public. <p align=justify> Top three Promoters holding highest number of shares of
  • Windlas Biotech - Analysts/Institutional Investor Meet/Con. Call Updates

    15 Apr 2026, 6:00PM Windlas Biotech Limited has informed the Exchange about Schedule of meet
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    15 Apr 2026, 5:48PM Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
  • Windlas Biotech - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    6 Apr 2026, 3:20PM Windlas Biotech Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended
  • Windlas Biotech - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    6 Apr 2026, 3:08PM Certificate under Regulation 74 (5) of the SEBl (Depositories and Participants) Regulations, 2018 for the Quarter ended March 31, 2026
  • Windlas Biotech - Trading Window

    25 Mar 2026, 6:09PM Windlas Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,
  • Windlas Biotech - Shareholders meeting

    20 Mar 2026, 12:54PM Windlas Biotech Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regardi
  • Windlas Biotech - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

    20 Mar 2026, 12:46PM Result of Postal Ballot
  • Windlas Biotech - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    20 Mar 2026, 12:37PM Result of Postal Ballot
  • Windlas Biotech - ESOP/ESOS/ESPS

    13 Mar 2026, 12:55PM Windlas Biotech Limited has informed the Exchange regarding Allotment of 28990 Shares under ESOP Scheme(s)
  • Windlas Biotech - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    13 Mar 2026, 12:45PM Allotment of equity shares pursuant to 'Windlas Biotech Limited- Employee Stock Option Plan 2021' and 'WBL Employee Stock Option Scheme 2023'
  • Windlas Biotech

    2 Feb 2022 , 9:47AM Windlass Biotech: The company’s plant IV at Dehradhun underwent an inspection from the SAPHRA (South African Health Products Regulatory Authority) between 20-29th September 2021. The inspection ended with zero critical observations/ deficiencies, zero major deficiencies and some minor deficiencies. This is positive as a successful inspection would open up new geography and help it strengthen its presence in South Africa.

Key fundamentals

Evaluate the intrinsic value of Windlas Biotech Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 610.708 532.905 450.4 403.109 401.247
Liabilities 610.708 532.905 450.4 403.109 401.247
Equity 10.553 10.48 10.399 10.463 10.897
Gross Profit 104.695 94.115 78.102 60.242 52.895
Net Profit 66.435 60.649 58.144 42.644 38.561
Cash From Operating Activities 104.927 68.232 108.911 60.982 8.997
NPM(%) 7.34 7.98 9.21 8.31 8.27
Revenue 904.089 759.878 630.956 513.083 465.93
Expenses 799.394 665.763 552.854 452.841 413.035
ROE(%) 12.1 11.04 10.59 7.76 7.02

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
6.3 126 0 782.35
21 Jul 2025 5.8 116 0 970.95
17 Sep 2024 5.5 110 0 607.95
09 Sep 2022 3.5 70 0 215.8

Peers

Other companies within the same industry or sector that are comparable to Windlas Biotech Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 705.80 -0.07 0.00 451.98 -26.19 0.71
Lotus Eye Hospital and Institute Ltd 109.19 1.26 352.23 1646.96 3.55 0.00
Vaishali Pharma Ltd 7.00 0.14 0.00 10331.95 3.13 0.00
Astec Lifesciences Ltd 771.80 4.77 0.00 1553.12 -363.15 0.00

Company Info

The Company was incorporated as `Windlas Biotech Limited' on February 19, 2001 at New Delhi as a public limited company under the Companies Act, 1956 and was granted a certificate of incorporation by RoC Delhi. Further, the Company received the certificate for commencement of business on March 5, 2001 from the RoC Delhi. The Registered Office of the Company was shifted from the state of Delhi to the state of Uttarakhand pursuant to a special resolution passed by the Shareholders on August 22, 2009. The alteration with respect to the place of the Registered Office was confirmed by the order of the Company Law Board, New Delhi on August 5, 2010 and a fresh certificate of registration was issued by the Registrar of Companies, Uttar Pradesh and Uttarakhand located at Kanpur on February 18, 2011. Subsequently, the Company was converted into a private limited company pursuant to a special resolution passed by the Shareholders on March 30, 2016 and a fresh certificate of incorporation consequent upon conversion and change of name to `Windlas Biotech Private Limited' was granted by the Registrar of Companies, Uttarakhand located at Kanpur on July 22, 2016. the Company was converted from a private limited company to a public limited company pursuant to a special resolution passed by the Shareholders on April 3, 2021, and the name of the Company was changed to `Windlas Biotech Limited'. A fresh certificate of incorporation dated April 15, 2021 consequent upon change of name on conversion to a public limited company was granted by the RoC.Major events and milestones of the Company :2001- Commenced operations at Dehradun Plant - I situated at 40/1, Mohabewala Industrial Area, Dehradun 248 110 and initiated commercial production2009- Commenced operations at Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 1102010- Revenues crossed Rs. 1,000 million for the FY 2009-102014- Received first USFDA inspection clearance for the WHC Plant- Revenues crossed Rs. 2,000 million for the FY 2013-14- Commenced operations at Dehradun Plant - II situated at khasra no. 141 to 143 and 145, Mohabewala Industrial Area, Dehradun 248 1102015- Investment of Rs. 750 million from Tano India Private Equity Fund II2017- Revenues crossed Rs. 3,000 million for the FY 2016-172018- Launched first product in the United States from the Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 110- Commenced operations at Dehradun Plant - III situated at plot no. 39, Pharmacity, Selaqui, Dehradun 248 1972021- Approval of Scheme of Amalgamation of the erstwhile subsidiary, Windlas Healthcare, with and into the Company 2022 -Company received certificate of Good Manufacturing Practices (GMP) from SAHPRA (South African Health Products Regulatory Authority).

The Company was incorporated as `Windlas Biotech Limited' on February 19, 2001 at New Delhi as a public limited company under the Companies Act, 1956 and was granted a certificate of incorporation by RoC Delhi. Further, the Company received the certificate for commencement of business on March 5, 2001 from the RoC Delhi. The Registered Office of the Company was shifted from the state of Delhi to the state of Uttarakhand pursuant to a special resolution passed by the Shareholders on August 22, 2009. The alteration with respect to the place of the Registered Office was confirmed by the order of the Company Law Board, New Delhi on August 5, 2010 and a fresh certificate of registration was issued by the Registrar of Companies, Uttar Pradesh and Uttarakhand located at Kanpur on February 18, 2011. Subsequently, the Company was converted into a private limited company pursuant to a special resolution passed by the Shareholders on March 30, 2016 and a fresh certificate of incorporation consequent upon conversion and change of name to `Windlas Biotech Private Limited' was granted by the Registrar of Companies, Uttarakhand located at Kanpur on July 22, 2016. the Company was converted from a private limited company to a public limited company pursuant to a special resolution passed by the Shareholders on April 3, 2021, and the name of the Company was changed to `Windlas Biotech Limited'. A fresh certificate of incorporation dated April 15, 2021 consequent upon change of name on conversion to a public limited company was granted by the RoC.Major events and milestones of the Company :2001- Commenced operations at Dehradun Plant - I situated at 40/1, Mohabewala Industrial Area, Dehradun 248 110 and initiated commercial production2009- Commenced operations at Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 1102010- Revenues crossed Rs. 1,000 million for the FY 2009-102014- Received first USFDA inspection clearance for the WHC Plant- Revenues crossed Rs. 2,000 million for the FY 2013-14- Commenced operations at Dehradun Plant - II situated at khasra no. 141 to 143 and 145, Mohabewala Industrial Area, Dehradun 248 1102015- Investment of Rs. 750 million from Tano India Private Equity Fund II2017- Revenues crossed Rs. 3,000 million for the FY 2016-172018- Launched first product in the United States from the Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 110- Commenced operations at Dehradun Plant - III situated at plot no. 39, Pharmacity, Selaqui, Dehradun 248 1972021- Approval of Scheme of Amalgamation of the erstwhile subsidiary, Windlas Healthcare, with and into the Company 2022 -Company received certificate of Good Manufacturing Practices (GMP) from SAHPRA (South African Health Products Regulatory Authority).

Parent Organisation

Windlas Biotech Ltd.

Founded

19/02/2001

Managing Director

Mr.Hitesh Windlass

NSE Symbol

WINDLASEQ

FAQ

OPEN FREE* DEMAT ACCOUNT